Terms: = Bone cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
16 results:
1. Resistance to immune checkpoint inhibitors in advanced lung cancer: clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract] [Full Text] [Related]
2. Treatment outcome of atypical egfr mutations in the German National Network Genomic Medicine Lung cancer (nNGM).
Janning M; Süptitz J; Albers-Leischner C; Delpy P; Tufman A; Velthaus-Rusik JL; Reck M; Jung A; Kauffmann-Guerrero D; Bonzheim I; Brändlein S; Hummel HD; Wiesweg M; Schildhaus HU; Stratmann JA; Sebastian M; Alt J; Buth J; Esposito I; Berger J; Tögel L; Saalfeld FC; Wermke M; Merkelbach-Bruse S; Hillmer AM; Klauschen F; Bokemeyer C; Buettner R; Wolf J; Loges S;
Ann Oncol; 2022 Jun; 33(6):602-615. PubMed ID: 35263633
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of egfr mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
Zeng Y; Guo T; Zhou Y; Zhao Y; Chu L; Chu X; Yang X; Ni J; Zhu Z
BMC Cancer; 2022 Feb; 22(1):198. PubMed ID: 35189835
[TBL] [Abstract] [Full Text] [Related]
4. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
5. High expression of Bruton's tyrosine kinase (BTK) is required for egfr-induced NF-κB activation and predicts poor prognosis in human glioma.
Yue C; Niu M; Shan QQ; Zhou T; Tu Y; Xie P; Hua L; Yu R; Liu X
J Exp Clin Cancer Res; 2017 Sep; 36(1):132. PubMed ID: 28946903
[TBL] [Abstract] [Full Text] [Related]
6. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.
Chang YP; Chen YM; Lai CH; Lin CY; Fang WF; Huang CH; Li SH; Chen HC; Wang CC; Lin MC
PLoS One; 2017; 12(6):e0178676. PubMed ID: 28591157
[TBL] [Abstract] [Full Text] [Related]
7. RECIST progression patterns during egfr tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an egfr mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract] [Full Text] [Related]
8. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract] [Full Text] [Related]
9. Combined point mutation in KRAS or egfr genes and EML4-ALK translocation in lung cancer patients.
Jürgens J; Engel-Riedel W; Prickartz A; Ludwig C; Schildgen O; Tillmann RL; Stoelben E; Brockmann M; Schildgen V
Future Oncol; 2014 Mar; 10(4):529-32. PubMed ID: 24754584
[TBL] [Abstract] [Full Text] [Related]
10. egfr intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
Vashist YK; Trump F; Gebauer F; Kutup A; Güngör C; Kalinin V; Muddasar R; Vettorazzi E; Yekebas EF; Brandt B; Pantel K; Izbicki JR
Target Oncol; 2014 Mar; 9(1):43-52. PubMed ID: 23377570
[TBL] [Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
[TBL] [Abstract] [Full Text] [Related]
12. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
[TBL] [Abstract] [Full Text] [Related]
13. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
[TBL] [Abstract] [Full Text] [Related]
14. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
[TBL] [Abstract] [Full Text] [Related]
15. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
[TBL] [Abstract] [Full Text] [Related]
16. A potential autocrine loop between heregulin-alpha and erbb-3 receptor in human prostatic adenocarcinoma.
Leung HY; Weston J; Gullick WJ; Williams G
Br J Urol; 1997 Feb; 79(2):212-6. PubMed ID: 9052472
[TBL] [Abstract] [Full Text] [Related]